Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 395 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: UNC Lineberger Comprehensive Cancer Center Clear all
Completed Phase 2 Interventional Results available

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

NCT02138617
View directory record Official record
Conditions
Colon Cancer
Interventions
5-Fluorouracil, Leucovorin, Irinotecan, Bevacizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 25, 2026, 4:13 AM EDT
Suspended Phase 2 Interventional

Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

NCT07639242
View directory record Official record
Conditions
Lung Cancer, Lung Cancer (NSCLC), Locally Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
Interventions
Olomorasib, Pembrolizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Terminated Not applicable Interventional

Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer

NCT04273724
View directory record Official record
Conditions
Bladder Cancer
Interventions
Targeted Interventions for Impairments Identified During Geriatric Assessment
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2021 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Visibility of Lesion Characteristics With Phase Contrast Mammography

NCT00467727
View directory record Official record
Conditions
Breast Cancer
Interventions
Phase Contrast Mammography
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
40 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

NCT01298570
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
Regorafenib (BAY 73-4506), FOLFIRI, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
23
States / cities
Denver, Colorado • Miami, Florida • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 1 Interventional

Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer

NCT00719173
View directory record Official record
Conditions
Breast Cancer, Nausea and Vomiting
Interventions
aprepitant, cyclophosphamide, placebo
Drug · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

NCT03620019
View directory record Official record
Conditions
Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin), Cutaneous Melanoma
Interventions
Denosumab, Pembrolizumab, Nivolumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Manchester, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer

NCT00499395
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
positron emission tomography, radiofrequency ablation
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Early Phase 1 Interventional

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

NCT01467310
View directory record Official record
Conditions
Breast Cancer
Interventions
GSK1120212
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting No phase listed Observational

Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT04099290
View directory record Official record
Conditions
Head and Neck Neoplasm, Carcinoma, Squamous Cell
Interventions
Blood and tumor samples
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes

NCT04974489
View directory record Official record
Conditions
Tobacco Use, Cigarette Use
Interventions
Emotion-based messages about the harm of VLNC, Continued-harm-framed messages about the harm of VLNC, Myth-refuting messages about the harm of VLNC, Control messages about littering
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases

NCT03281720
View directory record Official record
Conditions
Breast Cancer
Interventions
TAD
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting No phase listed Observational

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

NCT04564989
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Head and Neck Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
3
States / cities
Rochester, Minnesota • Chapel Hill, North Carolina • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women

NCT00099008
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer
Interventions
Genistein, Placebo
Dietary Supplement
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting Phase 1 Interventional

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

NCT03721068
View directory record Official record
Conditions
Neuroblastoma, Osteosarcoma
Interventions
iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Months and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2044
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

NCT06483555
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
Interventions
Gemcitabine, Nab paclitaxel, Erlotinib, NALIRIFOX, Folfirinox
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus

NCT00002984
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 25, 2026, 4:13 AM EDT
Completed No phase listed Observational

Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy

NCT01132833
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm, Thromboembolism
Interventions
enzyme-linked immunosorbent assay, laboratory biomarker analysis, medical chart review
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Sep 25, 2026, 4:13 AM EDT
Not yet recruiting Phase 2 Interventional

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

NCT07078838
View directory record Official record
Conditions
Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma
Interventions
Tirzepatide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed No phase listed Observational

Pre-Implementation Study of Improving Thoracic Surgical Care Using Electronic Patient-Reported Outcomes (ePROS)

NCT05311670
View directory record Official record
Conditions
Thoracic Surgery
Interventions
Patient-reported outcomes monitoring
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting Phase 1 Interventional

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

NCT03454035
View directory record Official record
Conditions
Tumor, Solid, Pancreatic Cancer, Melanoma
Interventions
Ulixertinib, Palbociclib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 1 Interventional

PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

NCT01169012
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 25, 2026, 4:13 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Decision Support Tool for Pancreatic Cancer Screening -Aim 2

NCT07808671
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Electronic Decision Support Tool
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed No phase listed Observational

Patient Preferences for Breast Reconstruction After Mastectomy

NCT01488357
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 25, 2026, 4:13 AM EDT